Full Press Release Details
Titan Pharmaceuticals Announces Debt
Settlement Agreement with Molteni and Horizon
South San Francisco, CA - October
26 2020 - Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), a company developing proprietary therapeutics for the treatment of select
chronic diseases utilizing its ProNeura long-term, continuous drug delivery technology, today announced its entry
into an agreement to settle all of its debt obligations with Molteni & C. dei F.lli Alitti Societ di Esercizio S.p.A
("Molteni) and Horizon Credit LLC II ("Horizon"). The debt was secured with a lien on all assets of Titan.
Under the terms of the agreement, Molteni
and Horizon agreed to settle the approximately $5.2 million of outstanding indebtedness in exchange for the payment by Titan of
a total of $1.6 million in cash to Horizon and Molteni, the transfer of certain Probuphine assets to Molteni, including
certain equipment, inventory and non-U.S. Probuphine intellectual property, and the termination of Titan's rights to future
payments under its asset purchase, supply and support agreement with Molteni.
"Reaching agreement on the settlement
of the outstanding debt is a major step in the restructuring of Titan, and we appreciate the timely action and cooperation of Molteni
and Horizon in accomplishing this goal," said Dr. DeVarney, President and Chief Operating Officer of Titan. "We are
making good progress in closing down the U.S. commercial activities for Probuphine, and except for the required pharmacovigilance
and REMS support to health care providers who have patients in treatment, we will have completed this task during the quarter."
The closing of the agreement is subject
to customary closing conditions and Titan's completion of a financing that will enable it to make the cash payments thereunder.
Upon closing, there will be no liens on Titan's remaining assets, including all the ProNeura intellectual
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP),
based in South San Francisco, CA, is a commercial stage company developing proprietary therapeutics with its ProNeura
long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products
for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit
the patient and improve medical outcomes. For more information about Titan, please visit www.titanpharm.com.
Forward-Looking Statements
This press release may contain "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act
of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other
statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business,
operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's
current expectations include those risks and uncertainties relating to our ability to raise capital, the winding down of U.S. commercial
activities related to Probuphine, the development, testing, production and regulatory approval process relating to our drug candidates,
patent and intellectual property matters and strategic agreements and relationships. We expressly disclaim any obligation or undertaking
to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations
or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.